SCHEDULE: Aberdeen Group plc Discloses 5.91% Stake in uniQure N.V.

Aberdeen Group plc and abrdn Inc. have disclosed a 5.91% beneficial ownership stake in uniQure N.V. as of December 31, 2025.

Summary

• Aberdeen Group plc and its subsidiary abrdn Inc. collectively hold beneficial ownership of 3,678,640 Ordinary Shares of uniQure N.V.
• This ownership represents 5.91% of uniQure N.V.'s outstanding Ordinary Shares.
• Both Aberdeen Group plc and abrdn Inc. exercise shared voting power and shared dispositive power over all 3,678,640 shares.
• Aberdeen Group plc is identified as a parent holding company, while abrdn Inc. is classified as an investment adviser and company.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of uniQure N.V.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain new financial or operational information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding uniQure N.V.'s future performance or operations.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant holdings by major investment firms. For uniQure N.V., a biotechnology company, the continued stake by a firm like abrdn Inc. indicates ongoing institutional interest in the gene therapy sector, which is characterized by high R&D costs and long development cycles.

Key Dates

Keywords

uniQure N.V., Aberdeen Group plc, abrdn Inc., Schedule 13G, beneficial ownership, institutional ownership, equity stake, biotechnology, gene therapy